Introduction
REXULTI, with the National Drug Code (NDC) 59148-0036, is a prescription drug manufactured by Otsuka America Pharmaceutical, Inc. It is a combination of brexpiprazole and aripiprazole, used primarily for the treatment of major depressive disorder (MDD) and schizophrenia. Here, we will delve into the market analysis and price projections for this medication.
Current Market Pricing
As of December 2024, the average pharmacy cost for REXULTI 0.5 MG tablets, identified by NDC 59148-0036, is approximately $47.00919 per unit[4].
Historical Price Trends
Historical data indicates that the prices of REXULTI have been relatively stable, with minor fluctuations. For instance, the price per unit for the 0.5 MG tablet has remained within a narrow range over recent months, suggesting a stable market demand and supply balance[4].
Wholesale Acquisition Costs (WAC)
The Wholesale Acquisition Costs (WAC) for prescription drugs are a critical factor in determining their retail prices. For REXULTI, the WAC is closely aligned with the average pharmacy cost, indicating that the drug's pricing is influenced by its wholesale acquisition price[4].
Regulatory and Transparency Efforts
Efforts to increase transparency in prescription drug pricing, such as those outlined in the Oregon Prescription Drug Price Transparency Program, aim to provide more insight into the factors influencing drug prices. These initiatives highlight the need for detailed information on pricing, including list prices, markups, rebates, and other cost factors that affect the final price to consumers[3][5].
Impact of Generic Competition
Although REXULTI is a brand-name drug, the broader pharmaceutical market is influenced by generic competition. For example, significant price reductions have been observed in generic drugs due to increased competition, as seen with generic fingolimod where prices dropped by 84% to 97% from their initial levels[3].
Medicare Drug Price Negotiation Program
The Medicare Drug Price Negotiation Program, part of the Inflation Reduction Act, aims to reduce prescription drug costs for Medicare beneficiaries. While REXULTI is not currently listed among the drugs selected for negotiation, the program's impact on other drugs could indirectly influence the pricing dynamics of the entire pharmaceutical market. For instance, negotiated prices for other drugs can set benchmarks and influence pricing strategies across the industry[2].
Price Projections
Given the current market stability and the absence of significant external factors such as generic competition or major regulatory changes, the price of REXULTI 0.5 MG tablets is expected to remain relatively stable in the short term.
- Short-term Projections (2025-2026): Prices are likely to fluctuate within a narrow range, reflecting minor adjustments due to inflation and market dynamics.
- Long-term Projections (2027 and beyond): The impact of broader market trends, such as increased transparency and potential changes in regulatory policies, could lead to more significant price adjustments. However, without specific changes in the drug's market environment, long-term prices are expected to remain relatively stable.
Key Factors Influencing Price
Several factors can influence the price of REXULTI:
- Market Demand: Stable demand for the drug due to its efficacy in treating MDD and schizophrenia.
- Regulatory Changes: Future changes in drug pricing transparency and negotiation programs could impact pricing strategies.
- Competition: The introduction of generic alternatives or new therapeutic options could affect market pricing.
- Economic Conditions: Inflation and economic downturns can influence pricing across the pharmaceutical sector.
Conclusion
The price of REXULTI 0.5 MG tablets, identified by NDC 59148-0036, is expected to remain stable in the short term, influenced by current market dynamics and the absence of significant external factors. Long-term projections suggest that prices could be affected by broader market trends and regulatory changes.
Key Takeaways
- Current Pricing: Approximately $47.00919 per unit as of December 2024.
- Historical Trends: Stable prices with minor fluctuations.
- Regulatory Impact: Increased transparency and negotiation programs could influence future pricing.
- Market Factors: Demand, competition, and economic conditions will continue to shape the drug's pricing.
FAQs
-
What is REXULTI used for?
REXULTI is used for the treatment of major depressive disorder (MDD) and schizophrenia.
-
What is the current price of REXULTI 0.5 MG tablets?
As of December 2024, the average pharmacy cost for REXULTI 0.5 MG tablets is approximately $47.00919 per unit.
-
How do regulatory efforts impact drug pricing?
Regulatory efforts, such as the Oregon Prescription Drug Price Transparency Program, aim to increase transparency and understanding of the factors influencing drug prices, which can lead to more informed policy decisions and potentially lower costs.
-
Will generic competition affect REXULTI prices?
Currently, REXULTI is a brand-name drug, but increased competition from generics in the broader market can set pricing benchmarks and influence industry pricing strategies.
-
How does the Medicare Drug Price Negotiation Program affect prescription drug prices?
The program negotiates prices for selected drugs under Medicare, which can set benchmarks and influence pricing across the pharmaceutical industry, although REXULTI is not currently included in these negotiations.
Sources
- FDA Report on ABILIFY - https://fda.report/NDC/59148-007
- Medicare Drug Price Negotiation Program - https://www.cms.gov/files/document/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf
- Oregon Prescription Drug Price Transparency Program Annual Report 2023 - https://dfr.oregon.gov/drugtransparency/Documents/20231207-dpt-hearing/Prescription-Drug-Price-Transparency-Annual-Report-2023.pdf
- Pharmaceutical Drug Prices and Trends for REXULTI - https://www.drugpatentwatch.com/p/drug-price/drugname/index.php?query=REXULTI
- Oregon Prescription Drug Price Transparency Results and Recommendations 2022 - https://dfr.oregon.gov/drugtransparency/Documents/Prescription-Drug-Price-Transparency-Annual-Report-2022.pdf
